Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction

International Journal of Impotence Research volume 16, pages 51–59 (2004)Cite this article

Abstract

PT-141, a cyclic heptapeptide melanocortin analog, was evaluated following intranasal administration in healthy male subjects and in Viagra-responsive erectile dysfunction (ED) patients. Erectile response was assessed by RigiScan™ in healthy subjects without visual sexual stimulation (VSS) and in Viagra®-responsive ED patients with VSS. In healthy subjects, mean Cmax and AUC(0–t) increased in a dose-dependent manner. Median Tmax was 0.50 h and mean t1/2 ranged from 1.85 to 2.09 h. In both studies, an erectile response induced by PT-141 administration was statistically significant, compared to placebo, at doses greater than 7 mg, with the onset of the first erection occurring in approximately 30 min. PT-141 was safely administered and well tolerated in both studies. A maximum-tolerated dose was not identified. Flushing and nausea were the most common adverse events reported in both studies and no clinically significant changes in vital signs, laboratory tests, ECGs, or physical exams were observed. Based upon its erectogenic potential and tolerability profile, PT-141 is a promising candidate for further evaluation as a treatment for male ED.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  1. Krane RJ, Goldstein I, Saenz De Tejada I . Impotence. N Engl J Med 1989; 321: 1648–1659.

    Article  CAS  Google Scholar 

  2. NIH Consensus Conference. Impotence. JAMA 1993; 270: 83–90.

  3. Furlow WL . Prevalence of impotence in the United States. Med Aspects Hum Sex 1985; 19: 13–16.

    Google Scholar 

  4. Kaiser FE . Erectile dysfunction in the aging man. Med Clin N Am 1999; 83: 1267–1278.

    Article  CAS  Google Scholar 

  5. Goldstein I et al. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998; 338: 1397–1404.

    Article  CAS  Google Scholar 

  6. Padma-Nathan H, Steers WD, Wicker PA . Efficacy and safety of oral sildenafil in the treatment of erectile dysfunction: a double-blind, placebo-controlled study of 329 patients. Int J Clin Pract 1998; 52: 375–379.

    CAS  Google Scholar 

  7. Stark S et al. Vardenafil increases penile rigidity and tumescence in men with erectile dysfunction after a single oral dose. Eur Urol 2001; 40: 181–190.

    Article  CAS  Google Scholar 

  8. Kuan J, Brock G . Selective phosphodiesterase type 5 inhibition using tadalafil for the treatment of erectile dysfunction. Expert Opin Invest Drugs 2002; 11: 1605–1613.

    Article  CAS  Google Scholar 

  9. Wessells H et al. Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction. Urology 2000; 56: 641–646.

    Article  CAS  Google Scholar 

  10. Rosen RC et al. The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822–830.

    Article  CAS  Google Scholar 

  11. Rosen RC, Cappelleri JC, Gendrano N . The International Index of Erectile Function (IIEF): a state-of-the-science review. Int J Impot Res 2002; 14: 226–244.

    Article  CAS  Google Scholar 

  12. Dula E, Bukofzer S, Perdok R, George M, Apomorphine SL Study Group. Double-blind, crossover comparison of 3 mg apomorphine SL with placebo and with 4 mg apomorphine SL in male erectile dysfunction. Eur Urol 2001; 39: 558–564.

    Article  CAS  Google Scholar 

  13. Heaton JPW, Dean J, Sleep DJ . Sequential administration enhances the effect of pomorphine SL in men with erectile dysfunction. Int J Impot Res 2002; 14: 61–64.

    Article  CAS  Google Scholar 

  14. Wikberg JE et al. New aspects on the melanocortins and their receptors. Pharmacol Res 2000; 42: 393–420.

    Article  CAS  Google Scholar 

  15. Argiolas A, Melis MR, Murgia S, Schioth HB . ACTH- and alpha-MSH-induced grooming, stretching, yawning and penile erection in male rats: site of action in the brain and role of melanocortin receptors. Brain Res Bull 2000; 51: 425–431.

    Article  CAS  Google Scholar 

  16. Argiolas A, Melis MR, Gessa GL . Yawning and penile erection: central dopamine–oxytocin–adrenocorticotropin connection. Ann NY Acad Sci 1988; 525: 330–337.

    Article  CAS  Google Scholar 

  17. Van der Ploeg LHT, Martin WJ, Howard AD, Nargund RP . A role for the melanocortin 4 receptor in sexual function. Proc Natl Acad Sci USA 2002; 99: 11381–11386.

    Article  CAS  Google Scholar 

  18. Udelson D et al. Axial penile buckling forces vs Rigiscan radial rigidity as a function of intracavernosal pressure: why Rigiscan does not predict functional erections in individual patients. Int J Impot Res 1999; 11: 327–337.

    Article  CAS  Google Scholar 

  19. Licht MR, Lewis RW, Wollan PC, Harris CD . Comparison of RigiScan and sleep laboratory nocturnal penile tumescence in the diagnosis of organic impotence. J Urol 1995; 154: 1740–1743.

    Article  CAS  Google Scholar 

  20. Kaneko S, Bradley WE . Evaluation of erectile dysfunction with continuous monitoring of penile rigidity. J Urol 1986; 136: 1026–1029.

    Article  CAS  Google Scholar 

  21. Ogrinc FG, Linet OI . Evaluation of real-time RigiScan monitoring in pharmacological erection. J Urol 1995; 154: 1356–1359.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank Annette Shadiack, Wilfredo Garcia, and Ramzey Odetalla for their valuable contributions to these studies

Author information

Authors and Affiliations

  1. Palatin Technologies, Inc., Cranbury, New Jersey, USA

    L E Diamond, D C Earle & P B Molinoff

  2. Department of Psychiatry, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, Piscataway, New Jersey, USA

    R C Rosen

  3. Advanced Biomedical Research, Pennington, New Jersey, USA

    M S Willett

Authors
  1. L E Diamond
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D C Earle
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R C Rosen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M S Willett
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P B Molinoff
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to L E Diamond.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Diamond, L., Earle, D., Rosen, R. et al. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res 16, 51–59 (2004). https://doi.org/10.1038/sj.ijir.3901139

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.ijir.3901139

Keywords

This article is cited by

Search

Advanced search

Quick links